Home Featured Page 159

Featured

Latest

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites

Psychedelic Funding Update: Q1 2026

Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida...

MindMed to Participate in H.C. Wainwright Global Investment ConferenceUSA – EnglishUSA...

PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™...

PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022

PT353 – Dr. James Fadiman, Dr. Sam Gandy, & Dr. David...

Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alochol...

Psychedelic Research Bulletin: July and August 2022

Wesana Announces Sale of Clinic Management Services Organization

MDMA Enhances Fear Extinction Learning: From Models to Mechanisms

PT352 – Alex Enchin & Ian-Michael Hébert, MA – HOLOS: Returning...

EDITOR PICKS

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines...

A Practitioner Statement on the Responsible Development of Ibogaine in the...

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.